The Pharmaletter

One To Watch

ARTBIO

A clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs).

The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. 

ARTBIO is advancing multiple pipeline programs with lead program AB001 in first-in-human trials as of Q1 2025.

Want to Update your Company's Profile?


More ARTBIO news >